Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., Dyer, M. J. S., Fegan, C., Oscier, D., Pettitt, A., Matutes, E., Devereux, S., Allsup, D., Bloor, A., Hillmen, P., Follows, G., Rule, S., Moss, P., & Stankovic, T. (2018). a multi‐centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T‐prolymphocytic leukaemia or mantle cell lymphoma. British journal of haematology, 182, 429–433. http://access.bl.uk/ark:/81055/vdc_100066550357.0x000060